ASP Isotopes (NASDAQ:ASPI) Shares Down 5.3% – Should You Sell?

Shares of ASP Isotopes Inc. (NASDAQ:ASPI) fell 5.3% during mid-day trading on Tuesday . The stock traded as low as $3.73 and last traded at $3.8050. Approximately 694,779 shares changed hands during trading, a decline of 85% from the average session volume of 4,787,871 shares. The stock had previously closed at $4.02.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on ASPI shares. Weiss Ratings reissued a “sell (d-)” rating on shares of ASP Isotopes in a research report on Wednesday, June 24th. Wall Street Zen upgraded ASP Isotopes from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $13.00.

ASP Isotopes Stock Performance

The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.85 and a current ratio of 3.87. The company has a market capitalization of $583.34 million, a price-to-earnings ratio of -2.89 and a beta of 3.61. The company’s fifty day simple moving average is $4.59 and its two-hundred day simple moving average is $5.24.

ASP Isotopes (NASDAQ:ASPI) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.11). ASP Isotopes had a negative return on equity of 64.99% and a negative net margin of 427.98%.The firm had revenue of $5.12 million during the quarter, compared to analyst estimates of $4.47 million.

Insider Transactions at ASP Isotopes

In other ASP Isotopes news, COO Robert Ainscow sold 8,438 shares of the business’s stock in a transaction on Monday, June 8th. The shares were sold at an average price of $7.00, for a total transaction of $59,066.00. Following the sale, the chief operating officer directly owned 2,281,879 shares of the company’s stock, valued at $15,973,153. The trade was a 0.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Michael Gorley sold 30,000 shares of the firm’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $6.27, for a total value of $188,100.00. Following the completion of the sale, the director directly owned 87,908 shares of the company’s stock, valued at approximately $551,183.16. This trade represents a 25.44% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 195,321 shares of company stock worth $1,354,855. 14.40% of the stock is currently owned by insiders.

Institutional Trading of ASP Isotopes

Large investors have recently added to or reduced their stakes in the business. HITE Hedge Asset Management LLC bought a new position in shares of ASP Isotopes in the 4th quarter valued at approximately $2,407,000. AWM Investment Company Inc. bought a new position in shares of ASP Isotopes in the second quarter worth about $9,837,000. Encompass Capital Advisors LLC acquired a new position in shares of ASP Isotopes during the 1st quarter worth about $30,551,000. BlackRock Inc. acquired a new position in shares of ASP Isotopes during the 2nd quarter worth about $57,331,000. Finally, SBI Securities Co. Ltd. boosted its stake in ASP Isotopes by 196.2% during the 4th quarter. SBI Securities Co. Ltd. now owns 152,120 shares of the company’s stock valued at $814,000 after purchasing an additional 100,769 shares during the period. 16.80% of the stock is owned by institutional investors.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.